Is Medicare Advantage a failed experiment?

The latest stories trending on MedCity News.

Editor's Pick

Top Story Is Medicare Advantage a Failed Experiment? Experts Debate Enrollment in Medicare Advantage is increasing, but the program has been drawing scrutiny from the government. Can the program be saved? One expert believes Medicare Advantage is a failed experiment. Another thinks that while the program has its flaws, it shows tremendous potential. Sponsored Content Navigating Healthcare's Data Revolution: Priorities, Opportunities, and Challenges for Health Systems Presented by Arcadia Arcadia recently partnered with HIMSS Market Insights to survey executives, IT, technology, and clinical leaders. Here's what we found. Learn More. Healthcare Is Not Scary Hurry and Save $100 off your INVEST Digital Health Ticket while it lasts. Ends 10/15 at 11:59pm ET. Use Promo Code FRIDAY13 and get your ticket now before Jason does. Register and Save Now

Featured News

Mercer Exec: Employers Are Extremely Concerned About Cost Cancer and pharmacy services are driving up costs for employers. One Mercer exec recently laid out several recommendations for employers to manage these costs. 3 Questions This Healthcare Investor Finds Herself Asking Startups All The Time At HLTH, General Catalyst Principal Candace Richardson discussed some of the questions she frequently asks startups during investment meetings. Some of these include "Do you stratify your outcomes data by different populations to ensure your model works well for everyone?" and "Is serving Medicaid populations on your roadmap?" Why the AMA President Thinks Scope of Practice Expansions Are a 'Terrible Idea' To address the growing physician shortage, some people argue that the scope of practice should be expanded for skilled healthcare professionals like nurse practitioners and pharmacists. American Medical Association President Dr. Jesse Ehrenfeld said this is a "terrible idea." He argued that throwing other professionals into physicians' roles will have poor ramifications of patient safety. In his view, the industry should focus on uplifting strong interprofessional care teams. Novo Nordisk's Star Diabetes & Obesity Drug Shows Promise in Kidney Disease A study testing Novo Nordisk's semaglutide in chronic kidney disease is ending early after an interim analysis met efficacy goals. Detailed results are not yet available, but they could support expanding use of the GLP-1 agonist, which is far and away Novo Nordisk's top-selling product.

Resources

MedCity Pivot Podcast: Tackling Rare Disease With Someone Who Was Touched By It Rich Horgan believes that there's an alternative path to drug development that can lower costs and the time it takes to bring drugs to market. He is trying to apply it to the field of rare and ultra-rare diseases. Listen Now

MedCity News • PO Box 901 • New York, NY unsubscribe